Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
RPRX's Cash to Debt is ranked higher than
97% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. RPRX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RPRX' s Cash to Debt Range Over the Past 10 Years
Min: 111  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.86
RPRX's Equity to Asset is ranked higher than
77% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. RPRX: 0.86 )
Ranked among companies with meaningful Equity to Asset only.
RPRX' s Equity to Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.87 Max: 0.98
Current: 0.86
0.19
0.98
Interest Coverage No Debt
RPRX's Interest Coverage is ranked higher than
96% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RPRX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
RPRX' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: -11.54
M-Score: -3.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -265381.82
RPRX's Operating margin (%) is ranked lower than
99% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. RPRX: -265381.82 )
Ranked among companies with meaningful Operating margin (%) only.
RPRX' s Operating margin (%) Range Over the Past 10 Years
Min: -624550  Med: -135601.07 Max: -908.49
Current: -265381.82
-624550
-908.49
Net-margin (%) -265381.82
RPRX's Net-margin (%) is ranked lower than
99% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. RPRX: -265381.82 )
Ranked among companies with meaningful Net-margin (%) only.
RPRX' s Net-margin (%) Range Over the Past 10 Years
Min: -624550  Med: -135601.07 Max: -908.49
Current: -265381.82
-624550
-908.49
ROE (%) -95.48
RPRX's ROE (%) is ranked lower than
80% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. RPRX: -95.48 )
Ranked among companies with meaningful ROE (%) only.
RPRX' s ROE (%) Range Over the Past 10 Years
Min: -336.72  Med: -129.11 Max: -55.84
Current: -95.48
-336.72
-55.84
ROA (%) -87.92
RPRX's ROA (%) is ranked lower than
85% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. RPRX: -87.92 )
Ranked among companies with meaningful ROA (%) only.
RPRX' s ROA (%) Range Over the Past 10 Years
Min: -237.27  Med: -105.43 Max: -52.9
Current: -87.92
-237.27
-52.9
ROC (Joel Greenblatt) (%) -167770.11
RPRX's ROC (Joel Greenblatt) (%) is ranked lower than
98% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. RPRX: -167770.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RPRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -145960  Med: -57122.72 Max: -24464.29
Current: -167770.11
-145960
-24464.29
EBITDA Growth (3Y)(%) 0.70
RPRX's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. RPRX: 0.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RPRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -51.7  Med: 0.70 Max: 68.8
Current: 0.7
-51.7
68.8
EPS Growth (3Y)(%) -0.90
RPRX's EPS Growth (3Y)(%) is ranked higher than
53% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. RPRX: -0.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RPRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -59.2  Med: 3.90 Max: 113.7
Current: -0.9
-59.2
113.7
» RPRX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-07)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

RPRX Guru Trades in Q1 2015

Chuck Royce 191,000 sh (-23.90%)
» More
Q2 2015

RPRX Guru Trades in Q2 2015

Jim Simons 202,143 sh (New)
Chuck Royce 191,000 sh (unchged)
» More
Q3 2015

RPRX Guru Trades in Q3 2015

Chuck Royce 129,000 sh (-32.46%)
Jim Simons 44,900 sh (-77.79%)
» More
Q4 2015

RPRX Guru Trades in Q4 2015

Chuck Royce 129,000 sh (unchged)
Jim Simons 33,913 sh (-24.47%)
» More
» Details

Insider Trades

Latest Guru Trades with RPRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.04
RPRX's P/B is ranked higher than
54% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. RPRX: 3.04 )
Ranked among companies with meaningful P/B only.
RPRX' s P/B Range Over the Past 10 Years
Min: 1.55  Med: 9.10 Max: 165.08
Current: 3.04
1.55
165.08
EV-to-EBIT -1.20
RPRX's EV-to-EBIT is ranked lower than
99.99% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.28 vs. RPRX: -1.20 )
Ranked among companies with meaningful EV-to-EBIT only.
RPRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.1  Med: -7.60 Max: -0.3
Current: -1.2
-31.1
-0.3
EV-to-EBITDA -1.20
RPRX's EV-to-EBITDA is ranked lower than
99.99% of the 276 Companies
in the Global Biotechnology industry.

( Industry Median: 20.97 vs. RPRX: -1.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
RPRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -31.5  Med: -7.70 Max: -0.3
Current: -1.2
-31.5
-0.3
Current Ratio 7.36
RPRX's Current Ratio is ranked higher than
66% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. RPRX: 7.36 )
Ranked among companies with meaningful Current Ratio only.
RPRX' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 7.89 Max: 51.39
Current: 7.36
0.86
51.39
Quick Ratio 7.36
RPRX's Quick Ratio is ranked higher than
67% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. RPRX: 7.36 )
Ranked among companies with meaningful Quick Ratio only.
RPRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 7.41 Max: 51.39
Current: 7.36
0.86
51.39

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.05
RPRX's Price/Net Cash is ranked higher than
72% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: 5.42 vs. RPRX: 3.05 )
Ranked among companies with meaningful Price/Net Cash only.
RPRX' s Price/Net Cash Range Over the Past 10 Years
Min: 0.46  Med: 4.62 Max: 48.04
Current: 3.05
0.46
48.04
Price/Net Current Asset Value 3.05
RPRX's Price/Net Current Asset Value is ranked higher than
71% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. RPRX: 3.05 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RPRX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.43  Med: 4.37 Max: 44.25
Current: 3.05
0.43
44.25
Price/Tangible Book 3.04
RPRX's Price/Tangible Book is ranked higher than
62% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. RPRX: 3.04 )
Ranked among companies with meaningful Price/Tangible Book only.
RPRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.42  Med: 4.50 Max: 36.25
Current: 3.04
0.42
36.25
Earnings Yield (Greenblatt) (%) -83.30
RPRX's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. RPRX: -83.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RPRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -5792.99  Med: 464.50 Max: 41501.3
Current: -83.3
-5792.99
41501.3

More Statistics

Revenue(Mil) $0
EPS $ -1.20
Beta0.38
Short Percentage of Float2.43%
52-Week Range $0.80 - 8.96
Shares Outstanding(Mil)24.32

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 0 0 0
EPS($) -0.95 -0.54 -0.91
EPS without NRI($) -0.95 -0.54 -0.91

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CHMA, LSE:MTPH, TSX:QLT, NAS:PIRS, XKLS:7178, ASX:ACR » details
Traded in other countries:ZONN.Germany,
Repros Therapeutics Inc was organized on August 20, 1987. The Company is a development stage biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's main product candidate, Androxal, is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. It is developing Androxal for men of reproductive age with low testosterone levels. Androxal treats the underlying mechanism that causes secondary hypogonadism and restores normal testicular function. The Company's second product candidate, Proellex for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. The Company recently completed a low dose study to demonstrate both safety and signals of efficacy in low oral doses of Proellex. The Company's research and development activities, preclinical studies and clinical trials, and the manufacturing, marketing and labeling of any products it may develop, are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK